Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) Biktarvy 2023 Sales: $11.850 billion Company/Developer: Gilead Sciences Date of First FDA Approval: February 7, 2018 Indications Biktarvy Is FDA-Approved for: HIV-1 List Price of Biktarvy: $3,981 per month Why It Sold So Well: Biktarvys $11.85 billion in sales accounted for almost 44 percent of Gileads overall product sales last year and more than half of the companys HIV portfolio, which is its biggest sales driver
Pfizer/Metsera is similar: buying a company with multiple assets (though after Metsera was public, not private)
Semaglutide in Obesity and Type 2 Diabetes Management: A Systematic Review of Clinical Outcomes
Download Pfizer Instructions for use
Where BPC-157 Fits (And Where It Doesnt) BPC-157 works best if it works at all when combined with: Proper rehab and movement Progressive loading Manual therapy or shockwave when appropriate Good nutrition and sleep Without movement, supplements have no direction
With a 5 mg/mL vial, 0.25 mg = 5 units